Treatment of lung large cell neuroendocrine carcinoma

Russo, Giuseppe Lo; Pusceddu, Sara; Proto, Claudia; Macerelli, Marianna; Signorelli, Diego; Vitali, Milena; Ganzinelli, Monica; Gallucci, Rosaria; Zilembo, Nicoletta; Platania, Marco; Buzzoni, Roberto; Braud, Filippo de; Garassino, Marina Chiara

doi:10.1007/s13277-016-5003-4

Cited by 54 publications

(48 citation statements)

References 82 publications

(102 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8 The role for adjuvant chemotherapy for stage I LCNEC after surgical resection remains unknown, and small-scale studies have yielded conflicting results. [9][10][11][12] Most of the studies have investigated platinum-based regimens. To our knowledge, only a single prospective adjuvant chemotherapy trial has been completed exclusively in patients with resected LCNEC; the results were suggestive of benefit from adjuvant cisplatin and etoposide.…”

Section: Introductionmentioning

confidence: 99%

The Role of Systemic Therapy in the Management of Stage I Large Cell Neuroendocrine Carcinoma of the Lung

Kujtan

Muthukumar

Kennedy

et al. 2018

Journal of Thoracic Oncology

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

The Role of Systemic Therapy in the Management of Stage I Large Cell Neuroendocrine Carcinoma of the Lung

Kujtan

Muthukumar

Kennedy

et al. 2018

Journal of Thoracic Oncology

View full text Add to dashboard Cite

show abstract

“…8,22,28 Since Travis et al first reported LCNEC in 1991, many authors have reported that LCNECs are aggressive tumors, and patients with these tumors have very poor prognoses. 8,12,17,19,22,23,28,29 Although LCNEC is categorized among the non-small cell lung carcinoma (NSCLC), the biological behavior of these tumors is very similar to that of small cell lung carcinoma (SCLC). Given the complex clinicopathological and biological features of LCNEC, there is controversy as to whether LCNEC should be treated according to NSCLC or SCLC protocols.…”

mentioning

confidence: 99%

Gamma Knife radiosurgery for brain metastases from pulmonary large cell neuroendocrine carcinoma: a Japanese multi-institutional cooperative study (JLGK1401)

Kawabe

Yamamoto

Sato

et al. 2016

JNS

View full text Add to dashboard Cite

OBJECTIVEIn 1999, the World Health Organization categorized large cell neuroendocrine carcinoma (LCNEC) of the lung as a variant of large cell carcinoma, and LCNEC now accounts for 3% of all lung cancers. Although LCNEC is categorized among the non–small cell lung cancers, its biological behavior has recently been suggested to be very similar to that of a small cell pulmonary malignancy. The clinical outcome for patients with LCNEC is generally poor, and the optimal treatment for this malignancy has not yet been established. Little information is available regarding management of LCNEC patients with brain metastases (METs). This study aimed to evaluate the efficacy of Gamma Knife radiosurgery (GKRS) for patients with brain METs from LCNEC.METHODSThe Japanese Leksell Gamma Knife Society planned this retrospective study in which 21 Gamma Knife centers in Japan participated. Data from 101 patients were reviewed for this study. Most of the patients with LCNEC were men (80%), and the mean age was 67 years (range 39–84 years). Primary lung tumors were reported as well controlled in one-third of the patients. More than half of the patients had extracranial METs. Brain metastasis and lung cancer had been detected simultaneously in 25% of the patients. Before GKRS, brain METs had manifested with neurological symptoms in 37 patients. Additionally, prior to GKRS, resection was performed in 17 patients and radiation therapy in 10. A small cell lung carcinoma–based chemotherapy regimen was chosen for 48 patients. The median lesion number was 3 (range 1–33). The median cumulative tumor volume was 3.5 cm3, and the median radiation dose was 20.0 Gy. For statistical analysis, the standard Kaplan-Meier method was used to determine post-GKRS survival. Competing risk analysis was applied to estimate GKRS cumulative incidences of maintenance of neurological function and death, local recurrence, appearance of new lesions, and complications.RESULTSThe overall median survival time (MST) was 9.6 months. MSTs for patients classified according to the modified recursive partitioning analysis (RPA) system were 25.7, 11.0, and 5.9 months for Class 1+2a (20 patients), Class 2b (28), and Class 3 (46), respectively. At 12 months after GKRS, neurological death–free and deterioration–free survival rates were 93% and 87%, respectively. Follow-up imaging studies were available in 78 patients. The tumor control rate was 86% at 12 months after GKRS.CONCLUSIONSThe present study suggests that GKRS is an effective treatment for LCNEC patients with brain METs, particularly in terms of maintaining neurological status.

show abstract

“…We need more cases to understand these tumors and to evaluate treatment regimens such as molecular-based therapy methods. 9,10…”

Section: Discussionmentioning

confidence: 99%

Large Cell Carcinoma With Adenocarcinoma In Lung

Küpeli

Köseoğlu

2018

J Coll Physicians Surg Pak

View full text Add to dashboard Cite

Large cell neuroendocrine carcinoma (LCNC) is a rare and aggressive cancer accounting for 3% of all lung cancers. A small percentage of LCNC called combined LCNC, can be seen in combinations with other lung tumor types. Multimodal therapy is proposed for this type of tumor but there is no any significant therapy since it is very rare tumor. This patient was a 66-year male and a heavy smoker with no symptoms of lung disease. Computed tomography core biopsy showed suspected adenocarcinoma. Right lower lobectomy was performed with mediastinal lymph node dissection via mini thoracotomy. The tumor was diagnosed as combined LCNC with adenocarcinoma. The patient was discharged on the seventh postoperative day and sent to the oncology clinic for chemotherapy. There has been no recurrence for eight months after surgery.

show abstract

Treatment of lung large cell neuroendocrine carcinoma

Cited by 54 publications

References 82 publications

The Role of Systemic Therapy in the Management of Stage I Large Cell Neuroendocrine Carcinoma of the Lung

The Role of Systemic Therapy in the Management of Stage I Large Cell Neuroendocrine Carcinoma of the Lung

Gamma Knife radiosurgery for brain metastases from pulmonary large cell neuroendocrine carcinoma: a Japanese multi-institutional cooperative study (JLGK1401)

Large Cell Carcinoma With Adenocarcinoma In Lung

Contact Info

Product

Resources

About